• Linkedin
  • Twitter
  • Youtube
  • Facebook
  • Instagram
HCS Pharma
  • Home
  • Services
    • Why HCS ?
    • Why BIOMIMESYS® 3D technology for HCS ?
    • Pharmacology
      • Neurodegenerative diseases
        • Parkinson
        • Alzheimer
      • Oncology
        • Cell cycle arrest
        • Cytotoxicity in 2D & 3D culture
        • Migration
      • Pharma custom assays
    • Toxicology
      • Genotoxicity
      • Hepatotoxicity
      • Neurotoxicity
    • Nutraceuticals
      • Inflammation
      • Lipid Peroxidation
      • Oxidative stress
      • Gut Microbiota
    • Dermocosmetology
      • Anti-redness
      • Extracellular matrix
      • Lipid peroxidation
      • Glutathione
      • Anti-Aging
      • Wound healing
      • Skin protection
      • Moisturizing
      • Skin microbiota
      • Cosmetics custom assays
  • About Us
    • Company
    • Team
    • Scientific Advisory Board
    • Join us
    • News
    • Partners
    • Privacy Policy
  • Posters
  • Pressroom
    • Press releases
    • Photos for the press
    • HCS Pharma in press
  • Contacts
    • How to contact us ?
    • Subscribe to our Newsletter
    • Show previous newsletters

genotoxicity

english

To be genotoxic, or not? That is the question!

Distinguishing aneugenic (chromosomes loss) from clastogenic effects (DNA damages) is essential to assess genotoxic properties of compounds. In order to help you taking the right decisions for your compounds, we developed a multiplex assay in order to discriminate aneugenic from clastogenic and cytotoxic effects of your compounds in one single Read more…

By Pierre Jean Ferron, 2 years2 years ago
english

See you next week on BioFIT 2017 event in Strasbourg!

Come and discover our programs on iPS and 3D culture

By Nathalie MAUBON, 2 years2 years ago
english

We were at “HCS plateforms day” of the the French Agency For Food and Safety

Last friday (10/11), we presented our neurotoxicity and genotoxicity assays at the French Agency for Food and Safety (ANSES)

By Pierre Jean Ferron, 2 years1 year ago
english

Our feedback of the 35th symposium of the French society of genetic toxicology in Marseille

We saw and participated to very interested sessions about genotoxic and epigenetic effects of environmental compounds

By Grégory MAUBON, 2 years2 years ago
english

Poster – Use of Automated High Content Analysis or Imaging Applied To Assessment Of Primary DNA Damage With γH2AX and Comet Assays on different Cell types

Genotoxicity potential assessment of pharmaceuticals is mandatory for registration. In addition to the standard in vitro/ in vivo test battery, other assays can be of interest because of their high throughput in the drug discovery stage but also for mechanistic understanding.

By Grégory MAUBON, 3 years2 years ago
english

Last day in Cosm’ing 2016

If you are in Cosm’ing meeting, don’t hesitate to go and discuss with Julian BURSZTYKA, our COO

By Nathalie MAUBON, 3 years3 years ago
HCSPharma-Galderma
english

Genotoxicity assay development in collaboration with Galderma R&D

During ELRIGfr event in Rennes, We had the opportunity to present our work on genotoxicity assay (comet assay on TK6 & gH2AX on keratinocytes and HepG2) in collaboration with the team of in vitro of Galderma R&D. It is really exciting to work with them since they are really experts Read more…

By Nathalie MAUBON, 4 years3 years ago
english

Poster – Development of an Automated Comet Assay for Genotoxicity Assessment on TK6 cell line

Quantifying DNA damage is mandatory to assess potential adverse effects of candidate drugs or molecules or extracts developed in the dermo-cosmetic industry, but also to assess the efficacy of therapeutic approaches with the aim of producing tumor cell genotoxicity in cancer treatment.

By Nathalie MAUBON, 4 years3 years ago
english

Our feedback of lab automation congress of ELRIGfr in Bruxelles

I was present at the last congress ELRIGfr in Brussels. It was a strong exchange place with interesting presentations around robotics. It is always really interesting to see examples of innovative automation which give really robust results.

By Nathalie MAUBON, 4 years3 years ago
english

Poster – Genotoxicity assays: assessment of double strand breaks through phospho-H2AX detection and micronuclei analysis in high content screening

Download our poster

By Grégory MAUBON, 4 years3 years ago
english

HCS Pharma presented two posters at ELRIGfr during forum labo 2015

Nathalie and Julian were present during ELRIGfr event last week. They presented their company, their work and their collaborations. They have also presented two posters, one on co-culture model of Parkinson and first results in 3D dimension, and the other one, on genotoxicity and steatosis assay on HepG2 cells.

By Nathalie MAUBON, 5 years3 years ago
english

Poster – HepG2 cell model for genotoxicity and steatosis assessment

Download our poster

By Grégory MAUBON, 5 years3 years ago
Your Needs
Pharmacology

Dermocosmetology

Toxicology

Nutraceuticals

[Our scientific posters]
Contacts
Contact us with this form!
Or
+33 769 999 137

Our Posters
  • Poster – Development and automation of 3D innovative hiPSC-based liver organoids including the microenvironment for phenotypic screening – Application on metabolic diseases
  • Poster – Development of a new liver-on-chip including BIOMIMESYS® technology for mimicking the liver extracellular matrix: first results and perspectives
  • Poster – A groundbreaking 3D cell culture technology for HCS: BIOMIMESYS hydroscaffold
  • Poster – Characterisation of 3D cultured primary human hepatocytes and HepaRG for DMSO-free preclinical toxicity testing
  • Poster (with Ncardia) – Neurotoxicity assessment: Comparison between SH-SY5Y and human iPSC-derived brain cells
  • Poster – Urine sample-derived human induced pluripotent stem cells as a model to study PCSK9-mediated autosomal dominant hypercholesterolemia
  • Poster – Neurotoxicity assay on 2D and 3D culture using High Content Screening (HCS) technology
  • Poster – In vitro dermocosmetology : high content analysis approach using human primary keratinocytes and fibroblasts
  • Poster – Use of Automated High Content Analysis or Imaging Applied To Assessment Of Primary DNA Damage With γH2AX and Comet Assays on different Cell types
  • Poster – Use of Automated High Content Analysis Applied To Assessment Of Primary DNA Damages With γH2AX and Comet Assays
Newsletter

Recent Posts
  • We’ll be at BioFit next week (with a great offer)!
  • Watch our tutorials for BIOMIMESYS® technology!
  • HCS Pharma recognized as a Deep Tech Pionner by Hello Tomorrow
  • Océane joins us to handle dermocosmetology projects!
  • Great business trip in Taiwan thanks to Molecular Devices and Tokyo Future style, Inc.!
Article en français
  • Merci à Eurasanté pour ce moment festif et convivial !
  • Do you want to talk with us at In-cosmetics Global 2019 ?
  • Développement d’un modèle cérébral in vitro en 3 dimensions (présentation au congrès de la SCMC)
  • Meilleur Voeux pour 2019 ! – Best wishes for 2019!
  • Vous avez des questions sur BIOMIMESYS® ? Utilisez notre F.A.Q. !
We talk about …
3D 3D cell culture 3D culture BIOMIMESYS BIOMIMESYS Brain blood brain barrier brain cancer cell congress cosmetic cosmetology data dermocosmetology digital drug ELRIG extracellular matrix forum labo genotoxicity HCA HCS hcs pharma High content screening imaging innovation in vitro IPS liver machine learning meeting Microbiota microscopy model Molecular Devices neurotoxicity oncology Parkinson phenotypic screening picture rennes screening skin toxicology wound healing
Choose where to go !
  • Home
  • Services
    • Why HCS ?
    • Why BIOMIMESYS® 3D technology for HCS ?
    • Pharmacology
      • Neurodegenerative diseases
        • Parkinson
        • Alzheimer
      • Oncology
        • Cell cycle arrest
        • Cytotoxicity in 2D & 3D culture
        • Migration
      • Pharma custom assays
    • Toxicology
      • Genotoxicity
      • Hepatotoxicity
      • Neurotoxicity
    • Nutraceuticals
      • Inflammation
      • Lipid Peroxidation
      • Oxidative stress
      • Gut Microbiota
    • Dermocosmetology
      • Anti-redness
      • Extracellular matrix
      • Lipid peroxidation
      • Glutathione
      • Anti-Aging
      • Wound healing
      • Skin protection
      • Moisturizing
      • Skin microbiota
      • Cosmetics custom assays
  • About Us
    • Company
    • Team
    • Scientific Advisory Board
    • Join us
    • News
    • Partners
    • Privacy Policy
  • Posters
  • Pressroom
    • Press releases
    • Photos for the press
    • HCS Pharma in press
  • Contacts
    • How to contact us ?
    • Subscribe to our Newsletter
    • Show previous newsletters
Recent Posts
  • We’ll be at BioFit next week (with a great offer)!
  • Watch our tutorials for BIOMIMESYS® technology!
  • HCS Pharma recognized as a Deep Tech Pionner by Hello Tomorrow
  • Océane joins us to handle dermocosmetology projects!
  • Great business trip in Taiwan thanks to Molecular Devices and Tokyo Future style, Inc.!
Contacts

HCS Pharma – Siège de Lille
Biocentre Fleming Bat A
250 rue Salvador Allende
59120 LOOS

HCS Pharma – Site de Rennes
Biopole
6 Rue Pierre Joseph Colin
35000 RENNES

Contact Us !
+33 769 999 137

Newsletter subcription
* = required field

powered by MailChimp!
Categories
  • Brittany Biotechnology (13)
  • english (380)
  • francais (16)
  • Hauts de France Biotechnology (6)
  • HCS, HCA & Biology (159)
  • Langue (272)
  • Meeting (111)
  • Our news (160)
  • Posters & Publications (19)
  • Uncategorized (12)
  • Home
  • Services
  • About Us
  • Posters
  • Pressroom
  • Contacts
HCS Pharma (c) 2019 | Hestia | Powered by WordPress
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.OkRead more